Titlebook: Mesothelioma; From Research to Cli Giovanni Luca Ceresoli,Emilio Bombardieri,Maurizio Book 2019 Springer Nature Switzerland AG 2019 Lung tu

我邪惡

Measuring Malignant Pleural Mesothelioma,tication. While anatomical T staging of mesothelioma currently incorporates only the extent of tumor invasion into adjacent structures, tumor burden is emerging as potentially important in this context and is the subject of current research. Assessment of the rate of change, or growth, of mesothelio

incubus

Role of Metabolic Imaging in Mesothelioma,. Computed tomography (CT) and magnetic resonance imaging (MRI) are routinely used for non-invasive clinical staging. Because of the complex growth pattern of MPM, it is difficult to make a clinical judgement only with morphological imaging, so .F-FDG PET-CT represent an important adjunctive imaging

永久

Pituitary-Gland

Surgery and Multimodality Treatment in Malignant Pleural Mesothelioma,t today there is no effective therapy for this tumor. Multimodality treatments, including the association of induction and/or adjuvant therapeutic regimens with surgery, have been reported to give encouraging results..The aim of surgical approach is to obtain a maximal cytoreduction and/or to contro

致命

HERTZ

吸引力

Targeting Angiogenesis in Malignant Pleural Mesothelioma,e. MPM patients have globally a poor prognosis with limited therapeutic options and no validated curative treatment. Therefore, innovative drugs and strategies are needed. Based on the preclinical rationale and first-trial data, antiangiogenic drugs have been tested in MPM, mostly associated with st

間接

Targeted Therapies in Mesothelioma,exed chemotherapy represents the current standard of care, and no indication is available for second-line treatments. So far, no targeted therapies proved to significantly impact the natural history of this neoplasm, thus reinforcing the need for new targets and drugs in MPM. In this chapter, we wil

嚴(yán)重傷害

TERRA

Immunotherapy of Mesothelioma: Vaccines and Cell Therapy,tion of platinum-based chemotherapy and an antifolate agent and leads to an overall survival of 9–12 months. Concurrent treatment with bevacizumab in addition to first-line treatment leads to a survival benefit of 2 months. Immunotherapy, namely checkpoint inhibition, has impacted the treatment of v